Predictions
CytoDyn Inc_INT
Start price
Target price
Perf. (%)
€2.10
23.10.20
23.10.20
€1.00
04.11.21
04.11.21
7.62%
04.11.20
04.11.20
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€54.61
23.10.20
23.10.20
€55.00
31.10.20
31.10.20
-8.91%
31.10.20
31.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€177.98
22.10.20
22.10.20
€170.00
04.11.21
04.11.21
-6.03%
05.11.21
05.11.21
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected
Thermo Fisher Scientific Inc.
Start price
Target price
Perf. (%)
€406.60
22.10.20
22.10.20
€580.00
04.11.21
04.11.21
37.09%
05.11.21
05.11.21
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Intuitive Surgical Inc
Start price
Target price
Perf. (%)
€201.33
22.10.20
22.10.20
€216.67
04.11.21
04.11.21
4.35%
07.11.20
07.11.20
Known brand
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€25.77
21.10.20
21.10.20
-
04.11.21
04.11.21
-36.63%
05.11.21
05.11.21
Risky Investment
Anavex Life Sciences Corp
Start price
Target price
Perf. (%)
€4.28
21.10.20
21.10.20
€6.00
04.11.21
04.11.21
348.60%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Misonix Inc.
Start price
Target price
Perf. (%)
€10.30
21.10.20
21.10.20
€12.00
02.11.20
02.11.20
-7.28%
02.11.20
02.11.20
Could be worthwhile Investment >10% per year
Hologic Inc.
Start price
Target price
Perf. (%)
€56.50
20.10.20
20.10.20
€60.00
04.11.21
04.11.21
-11.63%
07.06.21
07.06.21
Could be worthwhile Investment >10% per year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.42
20.10.20
20.10.20
€50.00
22.10.20
22.10.20
-1.26%
22.10.20
22.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Novacyt S.A.
Start price
Target price
Perf. (%)
€10.10
19.10.20
19.10.20
€4.00
30.10.20
30.10.20
14.26%
30.10.20
30.10.20
Probably not worthwhile Investment
Novacyt S.A.
Start price
Target price
Perf. (%)
€10.10
19.10.20
19.10.20
-
04.11.21
04.11.21
-72.31%
05.11.21
05.11.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Genmark Diagnostics
Start price
Target price
Perf. (%)
€9.65
19.10.20
19.10.20
€12.00
02.11.20
02.11.20
12.95%
02.11.20
02.11.20
Could be worthwhile Investment >10% per year
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€12.20
19.10.20
19.10.20
€15.00
02.11.20
02.11.20
-6.56%
02.11.20
02.11.20
Could be worthwhile Investment >10% per year
Cutera Inc.
Start price
Target price
Perf. (%)
€16.30
19.10.20
19.10.20
€20.00
02.11.20
02.11.20
-0.61%
02.11.20
02.11.20
Could be very worthwhile Investment >20% year
CHF Solutions Inc
Start price
Target price
Perf. (%)
-
19.10.20
19.10.20
€10.00
02.11.20
02.11.20
-
02.11.20
02.11.20
Could be very worthwhile Investment >20% year
Epigenomics AG NA
Start price
Target price
Perf. (%)
€0.51
18.10.20
18.10.20
€1.00
02.11.20
02.11.20
20.00%
02.11.20
02.11.20
Could be worthwhile Investment >10% per year
Capable Management
Very good company culture
Innovative
GNI Group Ltd
Start price
Target price
Perf. (%)
€24.00
18.10.20
18.10.20
€12.00
04.11.21
04.11.21
-35.42%
26.06.21
26.06.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
Below average Management
Little innovation
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€5.70
18.10.20
18.10.20
€2.00
04.11.21
04.11.21
-35.79%
26.06.21
26.06.21
Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€12.90
17.10.20
17.10.20
-
04.11.21
04.11.21
-29.07%
24.03.21
24.03.21
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Risky balance sheet
Medigene AG
Start price
Target price
Perf. (%)
€3.51
15.10.20
15.10.20
€5.00
19.10.20
19.10.20
0.28%
19.10.20
19.10.20
Could be worthwhile Investment >10% per year